News

First case this year without a documented occupational exposure to infected animals.

Mass distribution of azithromycin twice yearly to infants and children did not comply with WHO recommendation but reduced all-cause mortality.

James Graham, CEO discussed the company's progress in developing a new antibiotic for sepsis and diabetic foot ulcers.

Benjamin Park, MD, offers insights on the federal agency’s role in AMR.

Britton Strickland, MD discusses innovations in microbiome research and their impact on antimicrobial resistance.

Bala Subramanian, PhD, highlights how the novel antibiotic BWC0977, with its dual intravenous and oral formulation, is poised to transform the fight against antimicrobial resistance.

Jennifer Ronholm, PhD, discusses the novel concept of microbiome protection to create healthier animals and reduce antimicrobial usage.

Akhila Kosaraju, MD, addresses overcoming key challenges in antibiotic development using AI, a nonprofit model, and supportive policies.

Amanda Jezek, of the Infectious Diseases Society of America (IDSA), offers some insight on the prospective bill in Congress, as well as other AMR initiatives the organization is involved in.

Insights from Catherine Bertrand Ferrandis, DVM, on the role of One Health and interdisciplinary collaboration.

After Diane Shader Smith lost her daughter, Mallory, to a multidrug resistant infection, she turned her personal tragedy into a mission designed to inform people about antimicrobial resistance (AMR), and have the public coalesce around this expanding medical issue.

The Phase 1/2 study of VAX-31 demonstrated that the vaccine was well tolerated and elicited strong opsonophagocytic activity immune responses across all 31 evaluated serotypes.

Results in about 5.5 to 6 hours, employing advanced technology to detect bacterial growth and minimum inhibitory concentration.

Atea pharmaceuticals' oral nucleotide RNA-dependent RNA polymerase inhibitor advances in phase 3 trials for COVID-19 and phase 2 trials for hepatitis C, showing potential efficacy.

With antimicrobial drug shortages expected to continue globally, developing mitigation strategies is essential to prevent complications, including antimicrobial resistance.

As the WHO seeks Emergency Use Listing for new diagnostics due to rising cases in the Democratic Republic of the Congo, 50,000 doses of this vaccine will be donated to Central Africa.

Largest randomized trial of povidone iodine vs chlorhexidine gluconate could prompt WHO to recommend either over latter.

Study ranks antibiotic classes by risk for rare, life-threatening cutaneous reactions of Stevens-Johnson syndrome and toxic epidermal necrolysis.

This week, MP Biomedicals launched rapid diagnostic tests for gastrointestinal pathogens, Invivyd's monoclonal antibody pemivibart shows an 84% reduction in symptomatic COVID-19 risk, Nestlé is acquiring global rights to the Vowst therapy for CDI, and more.

Approved for individuals aged 12 years and older, this vaccine features a monovalent component and replaces the previous Novavax formula.

The most recent National Healthcare Safety Network annual survey shows that 78% of US hospitals now have sepsis committees, an increase from 73% in 2022.

The platform, PfizerForAll, looks to enable telemedicine for certain health conditions and information about vaccination access.

The FDA, CDC, and state health departments have been monitoring foodborne illnesses this August including Listeria, Salmonella, and Clostridium botulinum.

A study on vancomycin treatment, new data on the investigational Pfizer C diff vaccine, how individual antibiotics are ranked by risk for C difficile infection, and more.

As National Immunization Awareness Month concludes this August, it is a good time to review and update your vaccination schedules before the fall season begins.

In this episode, clinicians discuss challenges associated with these topics and offer management insights on them.

As with other metallo-β-lactamases, NDM is capable of hydrolyzing nearly all β-lactams, including carbapenems, and the search for the proper antimicrobials is challenging.

MP Biomedicals’ tests detect Helicobacter pylori, Salmonella typhi, and Vibrio cholerae serogroups O1 and O139.

Invivyd’s investigational pemivibart (Pemgarda), which received an FDA emergency use authorization earlier this year, continued to show efficacy in preventing disease onset over a 6-month exploratory period in this patient population.